Lidocaine HCI Topical Solution Recalled Due to Super Potency
The recalled lot of Lidocaine HCl Topical Solution 4% (40mg/mL) was distributed at the wholesale and retail distribution levels.
Treatment
Stereotactic Body Radiotherapy Aids Spinal Metastasis Pain
Stereotactic body radiotherapy is superior to conventional external beam radiotherapy for improving the complete response rate for pain associated with spinal metastasis.
Vagus Nerve Stimulation Improves Arm Function After Stroke
Researchers aimed to determine whether vagus nerve stimulation paired with rehabilitation is a safe and effective treatment for improving arm function lost after a stroke.
Calciphylaxis Prevention and Treatment Strategies
Calciphylaxis treatment should include a multimodal approach with a focus on supportive care, infection prevention, pain management, and wound healing.
FDA Approves Third COVID-19 Antibody Treatment for Emergency Use
A third antibody treatment designed to keep high-risk COVID-19 patients from being hospitalized was approved for emergency use by the US Food and Drug Administration on Wednesday.
Factors Identified Putting Youth on High-Risk Trajectory After First Opioid Treatment
High- and low-risk trajectories are identifiable for youth following their first opioid prescription.
Minocycline May Reduce Pain of Some Patients With Neuropathic Pain
The researchers reviewed studies evaluating the effectiveness of minocycline in alleviating neuropathic pain because it reduces microglial activation, which suggests that it may reduce neuropathic pain.
Number of Waddell Signs Correlate With Steroid Injection Treatment Failure
The number of Waddell signs present may indicate future treatment failure.
Eptinezumab May Significantly Reduce Migraine-Related Burden in Chronic Migraine
Eptinezumab treatment for chronic migraine was associated with significant reduction in migraine-related burden on work, home, and social functioning.
Non-Invasive Device Gets FDA Clearance for Migraine Treatment, Prevention in Younger Patients
The FDA has granted marketing clearance for eNeura’s single-pulse transcranial magnetic stimulation (sTMS) device for use in patients ≥12 years for the acute and prophylactic treatment of migraine.
- Loading...
Loading...
Next post in Migraine & Headache
Loading... 
Loading...